uniQure N.V. (NASDAQ:QURE) Sees Large Increase in Short Interest

uniQure N.V. (NASDAQ:QURE) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 11,996,689 shares, an increase of 33.8% from the December 15th total of 8,966,485 shares. Based on an average trading volume of 2,755,072 shares, the short-interest ratio is presently 4.4 days. Approximately 20.2% of the shares of the company are sold short. Approximately 20.2% of the shares of the company are sold short. Based on an average trading volume of 2,755,072 shares, the short-interest ratio is presently 4.4 days.

Insiders Place Their Bets

In other news, Director Jack Kaye sold 38,810 shares of the company’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total value of $1,177,495.40. Following the completion of the sale, the director directly owned 20,439 shares of the company’s stock, valued at approximately $620,119.26. This represents a 65.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Gut sold 31,434 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total value of $856,890.84. Following the sale, the director directly owned 40,145 shares of the company’s stock, valued at approximately $1,094,352.70. This represents a 43.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 102,247 shares of company stock worth $2,839,298 over the last ninety days. Corporate insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Several institutional investors have recently made changes to their positions in QURE. Aberdeen Group plc raised its position in shares of uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in uniQure by 31.2% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 67,739 shares of the biotechnology company’s stock worth $1,621,000 after acquiring an additional 16,126 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of uniQure by 508.1% in the 4th quarter. SG Americas Securities LLC now owns 64,326 shares of the biotechnology company’s stock worth $1,539,000 after purchasing an additional 53,747 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of uniQure in the 4th quarter valued at about $14,524,000. Finally, FNY Investment Advisers LLC grew its holdings in shares of uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on QURE. UBS Group set a $95.00 price objective on uniQure in a research report on Thursday, September 25th. Benchmark restated a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. Wells Fargo & Company dropped their price objective on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $60.82.

uniQure Trading Up 3.9%

NASDAQ:QURE traded up $0.86 during mid-day trading on Monday, reaching $22.84. The company’s stock had a trading volume of 1,562,144 shares, compared to its average volume of 1,778,902. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The stock has a market cap of $1.42 billion, a P/E ratio of -5.20 and a beta of 0.68. The company’s fifty day simple moving average is $24.77 and its two-hundred day simple moving average is $27.91. uniQure has a twelve month low of $7.76 and a twelve month high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The company had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. On average, equities analysts predict that uniQure will post -3.75 EPS for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.